Enteral Versus Parenteral Glutamine Supplement

NCT ID: NCT00875797

Last Updated: 2014-01-16

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-10-31
• Study Completion Date: 2009-03-31

Brief Summary

Glutamine is a major fuel for the intestinal tract and immune cells and therefore affects the intestinal permeability (IP) and infection rate at critically ill patients. The preferential route of glutamine supplementation at critically ill patients still remains open. Therefore the researchers will investigate IP, infection rate and treatment outcome at patients supplemented with either parenteral or enteral glutamine.

A prospective randomized single blind study is performed at mechanically ventilated. Patients were randomly assigned to either parenteral (group P) or enteral (group E) glutamine supplemented group. Early enteral feeding is started in both groups. Patients are/will be treated with glutamine for five days. IP will be measured using lactulose/mannitol test (L/M) on the fourth day.

Detailed Description

The patients who fulfilled the described criteria were randomly assigned to groups P or E using sequentially numbered containers for concealed randomization. Those in group P received the continuous infusion of parenteral glutamine dipeptide supplement (Dipeptiven 100ml, Fresenius Kabi) and were fed enterally with a standard commercial enteral polymeric diet without added glutamine (Ensure, Abbott Ross). The patients in group E received the enteral glutamine supplement as continuous administration of a standard commercial enteral diet supplemented with glutamine (Alitraq, Abbott Ross). The dose of the enteral glutamine, in a form of a free acid in this diet, depended on the volume of enteral food. Both groups of patients were treated with the glutamine supplement for five days. The other therapeutic procedures did not differ between the groups. All the patients were on continuous gastric feeding for 20 hours daily, starting with 20ml/hour. The enteral nutrition was started in 24 hours following admission. The gastric residual was measured three times daily, and when less than 250ml, the feeding volume was gradually increased up to 100ml/hour. If needed from day two onwards, the patients in all three groups received additional parenteral amino acid and glucose solutions to reach the goal 20kcal/kg/day and 0.15g nitrogen/kg/day.

Intestinal permeability (IP) was measured on day 4 using the lactulose/mannitol (L/M) test. For the study purpose, the patients were fasted 6 hours before the test. The test was performed with 5g of mannitol (M) and 10g of lactulose (L) mixed in 100ml of water. The mixture was given as a bolus via nasogastric tube. At the same time, 4ml of 20% chlorhexidine was added into an empty urine bag. The urine was collected in this bag for six hours. Then 5ml of urine was sampled from the bag and stored at -20˚C until analysis. Two hours after the test enteral feeding via nasogastric tube was started. Urinary L and M were determined simultaneously with thin-layer chromatography14, a new method in our laboratory for lactulose and mannitol determination. The method enabled determination of lactulose and mannitol in urine on the same amino HPTLC plate after densitometric quantification of lactulose by use of fluorescence mode, and mannitol by use of absorption mode after detection with AgNO3 reagent. The new method resulted in shorter analysis time, lower consumption of chemicals and HPTLC plates, increased sensitivity (lower limits of detection) and fewer problems with interfering compounds at determination of lactulose than the previously used two separate methods for determination of both analytes.14 The separation and quantification using this method are highly reproducible, yielding standard errors of less than 2.5% for retention times and less than 3.5% for quantitation.15,16 The investigators in the laboratory were blinded for the study groups. L/M index was calculated from urinary concentrations (c) of L and M using the following formula: L/M = c L / (c M x 2). L/M test was not performed at the beginning of the study because unstable trauma and septic patients were also included in the study, and at these patients, urine collection is difficult to perform.

Nosocomial infections were recorded during the entire ICU stay as recommended by the Centre for Disease Control in Atlanta.17,18 Nosocomial pneumonia was diagnosed when Hospital-Acquired Pneumonia Risk Index was 6 or more.19 The infections that were present upon admission or diagnosed within the first two days of ICU treatment were marked as acquired before ICU admission. All diagnosed infections were treated according to the results of microbiological tests and/or according to infection control guidelines. Acute inflammatory response was measured with C-reactive protein (CRP) levels. The blood samples for its determination were obtained at baseline and the end of the study.

Acute Physiology and Chronic Health Evaluation II (APACHE II) score was calculated upon admission. Each patient's ICU and hospital length of stay (LOS) and six month survival was recorded.

All participants were blinded to interventions. The ICU-staff was not blinded to group assignment, but they did not take part in the outcome assessment and on the other hand, the outcome assessors and laboratory personnel were blinded to group assignment.

Conditions

Critically Ill

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

parentral glutamine

parenteral glutamine given in central venous line in dose up to 30 g par day

Group Type: ACTIVE_COMPARATOR

parenteral glutamine

Intervention Type: DIETARY_SUPPLEMENT

Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day

entral glutamine

enteral glutamine given through gastric tube in a dose up to 30 g per day

Group Type: EXPERIMENTAL

enteral glutamine

Intervention Type: DIETARY_SUPPLEMENT

Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day

Interventions

parenteral glutamine

Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day

Intervention Type: DIETARY_SUPPLEMENT

enteral glutamine

Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day

Intervention Type: DIETARY_SUPPLEMENT

Other Intervention Names

Dipeptiven, Fresenius Kabi, Graz, Austria; Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands

Eligibility Criteria

Inclusion Criteria

• mechanically ventilated critically-ill patients
• older than 18 years
• staying in intensive care unit for at least 4 days

Exclusion Criteria

• anuria
• intestinal insufficiency (obstruction, discontinuation of intestine or severe ileus)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Medical Centre Ljubljana

OTHER

Sponsor Role: lead

Responsible Party

Lidija Kompan

MD, PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jasna Uranjek, MD

Role: PRINCIPAL_INVESTIGATOR

General Hospital Slovenj Gradec

Locations

General Hospital Slovenj Gradec

Slovenj Gradec, , Slovenia

Countries

Slovenia

References

Luo M, Bazargan N, Griffith DP, Estivariz CF, Leader LM, Easley KA, Daignault NM, Hao L, Meddings JB, Galloway JR, Blumberg JB, Jones DP, Ziegler TR. Metabolic effects of enteral versus parenteral alanyl-glutamine dipeptide administration in critically ill patients receiving enteral feeding: a pilot study. Clin Nutr. 2008 Apr;27(2):297-306. doi: 10.1016/j.clnu.2007.12.003. Epub 2008 Feb 7.

Reference Type: BACKGROUND

PMID: 18258342 (View on PubMed)

Other Identifiers

P4-0092: onko

Identifier Type: -

Identifier Source: org_study_id